Catalyst Wire Dossier Catalyst Wire Dossier

MKC253 inhalation powder

· MannKind Corporation
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MKC253 inhalation powder, covering 2012-06-14 to 2012-06-14. Get the full timeline:

Most recent: Clinical Trial Update: A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus [Phase 1]

See pricing